NasdaqGS:SVRABiotechs
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?
Recently, Savara announced that the US FDA accepted its biologics license application for MOLBREEVI for autoimmune pulmonary alveolar proteinosis, assigning a PDUFA target action date of November 22, while CFO David Lowrance exercised 580,187 stock options and sold 394,528 shares.
This regulatory milestone and executive share activity highlight both the advancing path toward a potential first-in-class therapy and how insiders are managing their equity exposure at a key moment for the...